SCYNEXIS, Inc.

SCYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SCYX stands at 36M. In comparison, TAK has a market cap of 56.1B. Regarding current trading prices, SCYX is priced at $0.89, while TAK trades at $18.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SCYX currently has a P/E ratio of -1.68, whereas TAK's P/E ratio is 80.75. In terms of profitability, SCYX's ROE is -0.19%, compared to TAK's ROE of +0.02%. Regarding short-term risk, SCYX is more volatile compared to TAK. This indicates potentially higher risk in terms of short-term price fluctuations for SCYX.Check TAK's competition here

SCYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SCYX stands at 36M. In comparison, ZTS has a market cap of 51B. Regarding current trading prices, SCYX is priced at $0.89, while ZTS trades at $117.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SCYX currently has a P/E ratio of -1.68, whereas ZTS's P/E ratio is 19.30. In terms of profitability, SCYX's ROE is -0.19%, compared to ZTS's ROE of +0.58%. Regarding short-term risk, SCYX is more volatile compared to ZTS. This indicates potentially higher risk in terms of short-term price fluctuations for SCYX.Check ZTS's competition here

SCYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SCYX stands at 36M. In comparison, HLN has a market cap of 44.7B. Regarding current trading prices, SCYX is priced at $0.89, while HLN trades at $10.37.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SCYX currently has a P/E ratio of -1.68, whereas HLN's P/E ratio is 20.08. In terms of profitability, SCYX's ROE is -0.19%, compared to HLN's ROE of +0.17%. Regarding short-term risk, SCYX is more volatile compared to HLN. This indicates potentially higher risk in terms of short-term price fluctuations for SCYX.Check HLN's competition here

SCYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SCYX stands at 36M. In comparison, TEVA has a market cap of 33.3B. Regarding current trading prices, SCYX is priced at $0.89, while TEVA trades at $29.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SCYX currently has a P/E ratio of -1.68, whereas TEVA's P/E ratio is 23.61. In terms of profitability, SCYX's ROE is -0.19%, compared to TEVA's ROE of +0.20%. Regarding short-term risk, SCYX is more volatile compared to TEVA. This indicates potentially higher risk in terms of short-term price fluctuations for SCYX.Check TEVA's competition here

SCYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SCYX stands at 36M. In comparison, VTRS has a market cap of 15.6B. Regarding current trading prices, SCYX is priced at $0.89, while VTRS trades at $13.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SCYX currently has a P/E ratio of -1.68, whereas VTRS's P/E ratio is -4.50. In terms of profitability, SCYX's ROE is -0.19%, compared to VTRS's ROE of -0.23%. Regarding short-term risk, SCYX is more volatile compared to VTRS. This indicates potentially higher risk in terms of short-term price fluctuations for SCYX.Check VTRS's competition here

SCYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SCYX stands at 36M. In comparison, ITCI has a market cap of 14B. Regarding current trading prices, SCYX is priced at $0.89, while ITCI trades at $131.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SCYX currently has a P/E ratio of -1.68, whereas ITCI's P/E ratio is -180.64. In terms of profitability, SCYX's ROE is -0.19%, compared to ITCI's ROE of -0.04%. Regarding short-term risk, SCYX is more volatile compared to ITCI. This indicates potentially higher risk in terms of short-term price fluctuations for SCYX.Check ITCI's competition here

SCYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SCYX stands at 36M. In comparison, NBIX has a market cap of 13B. Regarding current trading prices, SCYX is priced at $0.89, while NBIX trades at $130.58.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SCYX currently has a P/E ratio of -1.68, whereas NBIX's P/E ratio is 27.73. In terms of profitability, SCYX's ROE is -0.19%, compared to NBIX's ROE of +0.17%. Regarding short-term risk, SCYX is more volatile compared to NBIX. This indicates potentially higher risk in terms of short-term price fluctuations for SCYX.Check NBIX's competition here

SCYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SCYX stands at 36M. In comparison, RDY has a market cap of 11.8B. Regarding current trading prices, SCYX is priced at $0.89, while RDY trades at $13.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SCYX currently has a P/E ratio of -1.68, whereas RDY's P/E ratio is 19.35. In terms of profitability, SCYX's ROE is -0.19%, compared to RDY's ROE of +0.16%. Regarding short-term risk, SCYX is more volatile compared to RDY. This indicates potentially higher risk in terms of short-term price fluctuations for SCYX.Check RDY's competition here

SCYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SCYX stands at 36M. In comparison, CTLT has a market cap of 11.5B. Regarding current trading prices, SCYX is priced at $0.89, while CTLT trades at $63.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SCYX currently has a P/E ratio of -1.68, whereas CTLT's P/E ratio is -27.84. In terms of profitability, SCYX's ROE is -0.19%, compared to CTLT's ROE of -0.25%. Regarding short-term risk, SCYX is more volatile compared to CTLT. This indicates potentially higher risk in terms of short-term price fluctuations for SCYX.Check CTLT's competition here

SCYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SCYX stands at 36M. In comparison, RGC has a market cap of 11.5B. Regarding current trading prices, SCYX is priced at $0.89, while RGC trades at $23.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SCYX currently has a P/E ratio of -1.68, whereas RGC's P/E ratio is -2323.00. In terms of profitability, SCYX's ROE is -0.19%, compared to RGC's ROE of -0.62%. Regarding short-term risk, SCYX is more volatile compared to RGC. This indicates potentially higher risk in terms of short-term price fluctuations for SCYX.Check RGC's competition here

SCYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SCYX stands at 36M. In comparison, ELAN has a market cap of 11.4B. Regarding current trading prices, SCYX is priced at $0.89, while ELAN trades at $23.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SCYX currently has a P/E ratio of -1.68, whereas ELAN's P/E ratio is -48.82. In terms of profitability, SCYX's ROE is -0.19%, compared to ELAN's ROE of -0.04%. Regarding short-term risk, SCYX is more volatile compared to ELAN. This indicates potentially higher risk in terms of short-term price fluctuations for SCYX.Check ELAN's competition here

SCYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SCYX stands at 36M. In comparison, LNTH has a market cap of 5.3B. Regarding current trading prices, SCYX is priced at $0.89, while LNTH trades at $79.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SCYX currently has a P/E ratio of -1.68, whereas LNTH's P/E ratio is 23.31. In terms of profitability, SCYX's ROE is -0.19%, compared to LNTH's ROE of +0.21%. Regarding short-term risk, SCYX is more volatile compared to LNTH. This indicates potentially higher risk in terms of short-term price fluctuations for SCYX.Check LNTH's competition here

SCYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SCYX stands at 36M. In comparison, INDV has a market cap of 3.9B. Regarding current trading prices, SCYX is priced at $0.89, while INDV trades at $31.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SCYX currently has a P/E ratio of -1.68, whereas INDV's P/E ratio is 18.97. In terms of profitability, SCYX's ROE is -0.19%, compared to INDV's ROE of -0.99%. Regarding short-term risk, SCYX is more volatile compared to INDV. This indicates potentially higher risk in terms of short-term price fluctuations for SCYX.Check INDV's competition here

SCYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SCYX stands at 36M. In comparison, AMRX has a market cap of 3.7B. Regarding current trading prices, SCYX is priced at $0.89, while AMRX trades at $12.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SCYX currently has a P/E ratio of -1.68, whereas AMRX's P/E ratio is 53.77. In terms of profitability, SCYX's ROE is -0.19%, compared to AMRX's ROE of -0.68%. Regarding short-term risk, SCYX is more volatile compared to AMRX. This indicates potentially higher risk in terms of short-term price fluctuations for SCYX.Check AMRX's competition here

SCYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SCYX stands at 36M. In comparison, SUPN has a market cap of 2.9B. Regarding current trading prices, SCYX is priced at $0.89, while SUPN trades at $50.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SCYX currently has a P/E ratio of -1.68, whereas SUPN's P/E ratio is -73.40. In terms of profitability, SCYX's ROE is -0.19%, compared to SUPN's ROE of -0.00%. Regarding short-term risk, SCYX is more volatile compared to SUPN. This indicates potentially higher risk in terms of short-term price fluctuations for SCYX.Check SUPN's competition here

SCYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SCYX stands at 36M. In comparison, HCM has a market cap of 2.5B. Regarding current trading prices, SCYX is priced at $0.89, while HCM trades at $14.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SCYX currently has a P/E ratio of -1.68, whereas HCM's P/E ratio is 5.28. In terms of profitability, SCYX's ROE is -0.19%, compared to HCM's ROE of +0.42%. Regarding short-term risk, SCYX is more volatile compared to HCM. This indicates potentially higher risk in terms of short-term price fluctuations for SCYX.Check HCM's competition here

SCYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SCYX stands at 36M. In comparison, DCPH has a market cap of 2.2B. Regarding current trading prices, SCYX is priced at $0.89, while DCPH trades at $25.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SCYX currently has a P/E ratio of -1.68, whereas DCPH's P/E ratio is -11.58. In terms of profitability, SCYX's ROE is -0.19%, compared to DCPH's ROE of -0.56%. Regarding short-term risk, SCYX is more volatile compared to DCPH. This indicates potentially higher risk in terms of short-term price fluctuations for SCYX.Check DCPH's competition here

SCYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SCYX stands at 36M. In comparison, AVDL has a market cap of 2.1B. Regarding current trading prices, SCYX is priced at $0.89, while AVDL trades at $21.64.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SCYX currently has a P/E ratio of -1.68, whereas AVDL's P/E ratio is -1082.00. In terms of profitability, SCYX's ROE is -0.19%, compared to AVDL's ROE of -0.00%. Regarding short-term risk, SCYX is more volatile compared to AVDL. This indicates potentially higher risk in terms of short-term price fluctuations for SCYX.Check AVDL's competition here

SCYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SCYX stands at 36M. In comparison, PAHC has a market cap of 2B. Regarding current trading prices, SCYX is priced at $0.89, while PAHC trades at $50.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SCYX currently has a P/E ratio of -1.68, whereas PAHC's P/E ratio is 21.89. In terms of profitability, SCYX's ROE is -0.19%, compared to PAHC's ROE of +0.31%. Regarding short-term risk, SCYX is more volatile compared to PAHC. This indicates potentially higher risk in terms of short-term price fluctuations for SCYX.Check PAHC's competition here

SCYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SCYX stands at 36M. In comparison, EMBCV has a market cap of 1.9B. Regarding current trading prices, SCYX is priced at $0.89, while EMBCV trades at $33.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SCYX currently has a P/E ratio of -1.68, whereas EMBCV's P/E ratio is N/A. In terms of profitability, SCYX's ROE is -0.19%, compared to EMBCV's ROE of -0.28%. Regarding short-term risk, SCYX is less volatile compared to EMBCV. This indicates potentially lower risk in terms of short-term price fluctuations for SCYX.Check EMBCV's competition here

SCYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SCYX stands at 36M. In comparison, BHC has a market cap of 1.8B. Regarding current trading prices, SCYX is priced at $0.89, while BHC trades at $5.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SCYX currently has a P/E ratio of -1.68, whereas BHC's P/E ratio is 11.83. In terms of profitability, SCYX's ROE is -0.19%, compared to BHC's ROE of -0.20%. Regarding short-term risk, SCYX is more volatile compared to BHC. This indicates potentially higher risk in terms of short-term price fluctuations for SCYX.Check BHC's competition here

SCYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SCYX stands at 36M. In comparison, DVAX has a market cap of 1.8B. Regarding current trading prices, SCYX is priced at $0.89, while DVAX trades at $15.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SCYX currently has a P/E ratio of -1.68, whereas DVAX's P/E ratio is -41.89. In terms of profitability, SCYX's ROE is -0.19%, compared to DVAX's ROE of -0.08%. Regarding short-term risk, SCYX is more volatile compared to DVAX. This indicates potentially higher risk in terms of short-term price fluctuations for SCYX.Check DVAX's competition here

SCYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SCYX stands at 36M. In comparison, TARO has a market cap of 1.6B. Regarding current trading prices, SCYX is priced at $0.89, while TARO trades at $42.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SCYX currently has a P/E ratio of -1.68, whereas TARO's P/E ratio is 30.05. In terms of profitability, SCYX's ROE is -0.19%, compared to TARO's ROE of +0.03%. Regarding short-term risk, SCYX is more volatile compared to TARO. This indicates potentially higher risk in terms of short-term price fluctuations for SCYX.Check TARO's competition here

SCYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SCYX stands at 36M. In comparison, ANIP has a market cap of 1.6B. Regarding current trading prices, SCYX is priced at $0.89, while ANIP trades at $71.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SCYX currently has a P/E ratio of -1.68, whereas ANIP's P/E ratio is 21.23. In terms of profitability, SCYX's ROE is -0.19%, compared to ANIP's ROE of +0.16%. Regarding short-term risk, SCYX is more volatile compared to ANIP. This indicates potentially higher risk in terms of short-term price fluctuations for SCYX.Check ANIP's competition here

SCYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SCYX stands at 36M. In comparison, PRGO has a market cap of 1.3B. Regarding current trading prices, SCYX is priced at $0.89, while PRGO trades at $9.44.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SCYX currently has a P/E ratio of -1.68, whereas PRGO's P/E ratio is -0.92. In terms of profitability, SCYX's ROE is -0.19%, compared to PRGO's ROE of -0.35%. Regarding short-term risk, SCYX is more volatile compared to PRGO. This indicates potentially higher risk in terms of short-term price fluctuations for SCYX.Check PRGO's competition here

SCYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SCYX stands at 36M. In comparison, HROW has a market cap of 1.3B. Regarding current trading prices, SCYX is priced at $0.89, while HROW trades at $34.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SCYX currently has a P/E ratio of -1.68, whereas HROW's P/E ratio is -243.57. In terms of profitability, SCYX's ROE is -0.19%, compared to HROW's ROE of -0.10%. Regarding short-term risk, SCYX is more volatile compared to HROW. This indicates potentially higher risk in terms of short-term price fluctuations for SCYX.Check HROW's competition here

SCYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SCYX stands at 36M. In comparison, COLL has a market cap of 1.1B. Regarding current trading prices, SCYX is priced at $0.89, while COLL trades at $35.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SCYX currently has a P/E ratio of -1.68, whereas COLL's P/E ratio is 19.94. In terms of profitability, SCYX's ROE is -0.19%, compared to COLL's ROE of +0.24%. Regarding short-term risk, SCYX is more volatile compared to COLL. This indicates potentially higher risk in terms of short-term price fluctuations for SCYX.Check COLL's competition here

SCYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SCYX stands at 36M. In comparison, ALVO has a market cap of 1.1B. Regarding current trading prices, SCYX is priced at $0.89, while ALVO trades at $3.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SCYX currently has a P/E ratio of -1.68, whereas ALVO's P/E ratio is 15.09. In terms of profitability, SCYX's ROE is -0.19%, compared to ALVO's ROE of -0.26%. Regarding short-term risk, SCYX is more volatile compared to ALVO. This indicates potentially higher risk in terms of short-term price fluctuations for SCYX.Check ALVO's competition here

SCYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SCYX stands at 36M. In comparison, PCRX has a market cap of 1B. Regarding current trading prices, SCYX is priced at $0.89, while PCRX trades at $23.56.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SCYX currently has a P/E ratio of -1.68, whereas PCRX's P/E ratio is 145.38. In terms of profitability, SCYX's ROE is -0.19%, compared to PCRX's ROE of +0.01%. Regarding short-term risk, SCYX is more volatile compared to PCRX. This indicates potentially higher risk in terms of short-term price fluctuations for SCYX.Check PCRX's competition here

SCYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SCYX stands at 36M. In comparison, CRON has a market cap of 961.5M. Regarding current trading prices, SCYX is priced at $0.89, while CRON trades at $2.56.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SCYX currently has a P/E ratio of -1.68, whereas CRON's P/E ratio is -125.00. In terms of profitability, SCYX's ROE is -0.19%, compared to CRON's ROE of -0.01%. Regarding short-term risk, SCYX is more volatile compared to CRON. This indicates potentially higher risk in terms of short-term price fluctuations for SCYX.Check CRON's competition here

SCYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SCYX stands at 36M. In comparison, PETQ has a market cap of 919.2M. Regarding current trading prices, SCYX is priced at $0.89, while PETQ trades at $30.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SCYX currently has a P/E ratio of -1.68, whereas PETQ's P/E ratio is 83.73. In terms of profitability, SCYX's ROE is -0.19%, compared to PETQ's ROE of +0.01%. Regarding short-term risk, SCYX is more volatile compared to PETQ. This indicates potentially higher risk in terms of short-term price fluctuations for SCYX.Check PETQ's competition here

SCYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SCYX stands at 36M. In comparison, AMPH has a market cap of 835.4M. Regarding current trading prices, SCYX is priced at $0.89, while AMPH trades at $19.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SCYX currently has a P/E ratio of -1.68, whereas AMPH's P/E ratio is 8.96. In terms of profitability, SCYX's ROE is -0.19%, compared to AMPH's ROE of +0.13%. Regarding short-term risk, SCYX is more volatile compared to AMPH. This indicates potentially higher risk in terms of short-term price fluctuations for SCYX.Check AMPH's competition here

SCYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SCYX stands at 36M. In comparison, EVO has a market cap of 821M. Regarding current trading prices, SCYX is priced at $0.89, while EVO trades at $2.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SCYX currently has a P/E ratio of -1.68, whereas EVO's P/E ratio is -4.44. In terms of profitability, SCYX's ROE is -0.19%, compared to EVO's ROE of -0.17%. Regarding short-term risk, SCYX is more volatile compared to EVO. This indicates potentially higher risk in terms of short-term price fluctuations for SCYX.Check EVO's competition here

SCYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SCYX stands at 36M. In comparison, TLRY has a market cap of 697.6M. Regarding current trading prices, SCYX is priced at $0.89, while TLRY trades at $6.88.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SCYX currently has a P/E ratio of -1.68, whereas TLRY's P/E ratio is -0.29. In terms of profitability, SCYX's ROE is -0.19%, compared to TLRY's ROE of -1.14%. Regarding short-term risk, SCYX is more volatile compared to TLRY. This indicates potentially higher risk in terms of short-term price fluctuations for SCYX.Check TLRY's competition here

SCYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SCYX stands at 36M. In comparison, BDSI has a market cap of 577.1M. Regarding current trading prices, SCYX is priced at $0.89, while BDSI trades at $5.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SCYX currently has a P/E ratio of -1.68, whereas BDSI's P/E ratio is 6.82. In terms of profitability, SCYX's ROE is -0.19%, compared to BDSI's ROE of +0.57%. Regarding short-term risk, SCYX is more volatile compared to BDSI. This indicates potentially higher risk in terms of short-term price fluctuations for SCYX.Check BDSI's competition here

SCYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SCYX stands at 36M. In comparison, IRWD has a market cap of 549.5M. Regarding current trading prices, SCYX is priced at $0.89, while IRWD trades at $3.37.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SCYX currently has a P/E ratio of -1.68, whereas IRWD's P/E ratio is 22.47. In terms of profitability, SCYX's ROE is -0.19%, compared to IRWD's ROE of -0.08%. Regarding short-term risk, SCYX is more volatile compared to IRWD. This indicates potentially higher risk in terms of short-term price fluctuations for SCYX.Check IRWD's competition here

SCYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SCYX stands at 36M. In comparison, CGC has a market cap of 524.8M. Regarding current trading prices, SCYX is priced at $0.89, while CGC trades at $1.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SCYX currently has a P/E ratio of -1.68, whereas CGC's P/E ratio is -0.74. In terms of profitability, SCYX's ROE is -0.19%, compared to CGC's ROE of -0.53%. Regarding short-term risk, SCYX is more volatile compared to CGC. This indicates potentially higher risk in terms of short-term price fluctuations for SCYX.Check CGC's competition here

SCYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SCYX stands at 36M. In comparison, EMBC has a market cap of 520.5M. Regarding current trading prices, SCYX is priced at $0.89, while EMBC trades at $8.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SCYX currently has a P/E ratio of -1.68, whereas EMBC's P/E ratio is 3.72. In terms of profitability, SCYX's ROE is -0.19%, compared to EMBC's ROE of -0.21%. Regarding short-term risk, SCYX is more volatile compared to EMBC. This indicates potentially higher risk in terms of short-term price fluctuations for SCYX.Check EMBC's competition here

SCYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SCYX stands at 36M. In comparison, KMDA has a market cap of 501.8M. Regarding current trading prices, SCYX is priced at $0.89, while KMDA trades at $8.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SCYX currently has a P/E ratio of -1.68, whereas KMDA's P/E ratio is 24.86. In terms of profitability, SCYX's ROE is -0.19%, compared to KMDA's ROE of +0.08%. Regarding short-term risk, SCYX is more volatile compared to KMDA. This indicates potentially higher risk in terms of short-term price fluctuations for SCYX.Check KMDA's competition here

SCYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SCYX stands at 36M. In comparison, ESPR has a market cap of 482M. Regarding current trading prices, SCYX is priced at $0.89, while ESPR trades at $2.68.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SCYX currently has a P/E ratio of -1.68, whereas ESPR's P/E ratio is -4.52. In terms of profitability, SCYX's ROE is -0.19%, compared to ESPR's ROE of +0.06%. Regarding short-term risk, SCYX is more volatile compared to ESPR. This indicates potentially higher risk in terms of short-term price fluctuations for SCYX.Check ESPR's competition here

SCYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SCYX stands at 36M. In comparison, EBS has a market cap of 423.6M. Regarding current trading prices, SCYX is priced at $0.89, while EBS trades at $8.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SCYX currently has a P/E ratio of -1.68, whereas EBS's P/E ratio is 8.67. In terms of profitability, SCYX's ROE is -0.19%, compared to EBS's ROE of +0.10%. Regarding short-term risk, SCYX is more volatile compared to EBS. This indicates potentially higher risk in terms of short-term price fluctuations for SCYX.Check EBS's competition here

SCYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SCYX stands at 36M. In comparison, AQST has a market cap of 399.2M. Regarding current trading prices, SCYX is priced at $0.89, while AQST trades at $4.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SCYX currently has a P/E ratio of -1.68, whereas AQST's P/E ratio is -5.74. In terms of profitability, SCYX's ROE is -0.19%, compared to AQST's ROE of +1.96%. Regarding short-term risk, SCYX is more volatile compared to AQST. This indicates potentially higher risk in terms of short-term price fluctuations for SCYX.Check AQST's competition here

SCYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SCYX stands at 36M. In comparison, SNDL has a market cap of 388.8M. Regarding current trading prices, SCYX is priced at $0.89, while SNDL trades at $1.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SCYX currently has a P/E ratio of -1.68, whereas SNDL's P/E ratio is -5.81. In terms of profitability, SCYX's ROE is -0.19%, compared to SNDL's ROE of -0.08%. Regarding short-term risk, SCYX is more volatile compared to SNDL. This indicates potentially higher risk in terms of short-term price fluctuations for SCYX.Check SNDL's competition here

SCYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SCYX stands at 36M. In comparison, SIGA has a market cap of 376.7M. Regarding current trading prices, SCYX is priced at $0.89, while SIGA trades at $5.44.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SCYX currently has a P/E ratio of -1.68, whereas SIGA's P/E ratio is 5.11. In terms of profitability, SCYX's ROE is -0.19%, compared to SIGA's ROE of +0.00%. Regarding short-term risk, SCYX is more volatile compared to SIGA. This indicates potentially higher risk in terms of short-term price fluctuations for SCYX.Check SIGA's competition here

SCYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SCYX stands at 36M. In comparison, ORGO has a market cap of 339.6M. Regarding current trading prices, SCYX is priced at $0.89, while ORGO trades at $2.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SCYX currently has a P/E ratio of -1.68, whereas ORGO's P/E ratio is 17.60. In terms of profitability, SCYX's ROE is -0.19%, compared to ORGO's ROE of +0.10%. Regarding short-term risk, SCYX is more volatile compared to ORGO. This indicates potentially higher risk in terms of short-term price fluctuations for SCYX.Check ORGO's competition here

SCYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SCYX stands at 36M. In comparison, EOLS has a market cap of 326M. Regarding current trading prices, SCYX is priced at $0.89, while EOLS trades at $5.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SCYX currently has a P/E ratio of -1.68, whereas EOLS's P/E ratio is -6.19. In terms of profitability, SCYX's ROE is -0.19%, compared to EOLS's ROE of +2.68%. Regarding short-term risk, SCYX is more volatile compared to EOLS. This indicates potentially higher risk in terms of short-term price fluctuations for SCYX.Check EOLS's competition here

SCYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SCYX stands at 36M. In comparison, ALIM has a market cap of 301.3M. Regarding current trading prices, SCYX is priced at $0.89, while ALIM trades at $5.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SCYX currently has a P/E ratio of -1.68, whereas ALIM's P/E ratio is 5.28. In terms of profitability, SCYX's ROE is -0.19%, compared to ALIM's ROE of -1.59%. Regarding short-term risk, SCYX is more volatile compared to ALIM. This indicates potentially higher risk in terms of short-term price fluctuations for SCYX.Check ALIM's competition here

SCYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SCYX stands at 36M. In comparison, LNDC has a market cap of 263.6M. Regarding current trading prices, SCYX is priced at $0.89, while LNDC trades at $8.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SCYX currently has a P/E ratio of -1.68, whereas LNDC's P/E ratio is -4.04. In terms of profitability, SCYX's ROE is -0.19%, compared to LNDC's ROE of -15.33%. Regarding short-term risk, SCYX is more volatile compared to LNDC. This indicates potentially higher risk in terms of short-term price fluctuations for SCYX.Check LNDC's competition here

SCYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SCYX stands at 36M. In comparison, LFCR has a market cap of 245M. Regarding current trading prices, SCYX is priced at $0.89, while LFCR trades at $4.78.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SCYX currently has a P/E ratio of -1.68, whereas LFCR's P/E ratio is -5.15. In terms of profitability, SCYX's ROE is -0.19%, compared to LFCR's ROE of -2.33%. Regarding short-term risk, SCYX is less volatile compared to LFCR. This indicates potentially lower risk in terms of short-term price fluctuations for SCYX.Check LFCR's competition here

SCYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SCYX stands at 36M. In comparison, TYHT has a market cap of 229.2M. Regarding current trading prices, SCYX is priced at $0.89, while TYHT trades at $11.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SCYX currently has a P/E ratio of -1.68, whereas TYHT's P/E ratio is -1.61. In terms of profitability, SCYX's ROE is -0.19%, compared to TYHT's ROE of -0.65%. Regarding short-term risk, SCYX is more volatile compared to TYHT. This indicates potentially higher risk in terms of short-term price fluctuations for SCYX.Check TYHT's competition here

SCYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SCYX stands at 36M. In comparison, BGM has a market cap of 202.6M. Regarding current trading prices, SCYX is priced at $0.89, while BGM trades at $0.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SCYX currently has a P/E ratio of -1.68, whereas BGM's P/E ratio is -3.48. In terms of profitability, SCYX's ROE is -0.19%, compared to BGM's ROE of -0.03%. Regarding short-term risk, SCYX is more volatile compared to BGM. This indicates potentially higher risk in terms of short-term price fluctuations for SCYX.Check BGM's competition here

SCYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SCYX stands at 36M. In comparison, ACB has a market cap of 194.5M. Regarding current trading prices, SCYX is priced at $0.89, while ACB trades at $3.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SCYX currently has a P/E ratio of -1.68, whereas ACB's P/E ratio is -3.12. In terms of profitability, SCYX's ROE is -0.19%, compared to ACB's ROE of -0.08%. Regarding short-term risk, SCYX is more volatile compared to ACB. This indicates potentially higher risk in terms of short-term price fluctuations for SCYX.Check ACB's competition here

SCYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SCYX stands at 36M. In comparison, OGI has a market cap of 190.5M. Regarding current trading prices, SCYX is priced at $0.89, while OGI trades at $1.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SCYX currently has a P/E ratio of -1.68, whereas OGI's P/E ratio is 11.75. In terms of profitability, SCYX's ROE is -0.19%, compared to OGI's ROE of +0.05%. Regarding short-term risk, SCYX is more volatile compared to OGI. This indicates potentially higher risk in terms of short-term price fluctuations for SCYX.Check OGI's competition here

SCYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SCYX stands at 36M. In comparison, REPH has a market cap of 177.4M. Regarding current trading prices, SCYX is priced at $0.89, while REPH trades at $2.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SCYX currently has a P/E ratio of -1.68, whereas REPH's P/E ratio is -8.04. In terms of profitability, SCYX's ROE is -0.19%, compared to REPH's ROE of -0.22%. Regarding short-term risk, SCYX is more volatile compared to REPH. This indicates potentially higher risk in terms of short-term price fluctuations for SCYX.Check REPH's competition here

SCYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SCYX stands at 36M. In comparison, DERM has a market cap of 166.4M. Regarding current trading prices, SCYX is priced at $0.89, while DERM trades at $7.64.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SCYX currently has a P/E ratio of -1.68, whereas DERM's P/E ratio is -20.63. In terms of profitability, SCYX's ROE is -0.19%, compared to DERM's ROE of -0.40%. Regarding short-term risk, SCYX is more volatile compared to DERM. This indicates potentially higher risk in terms of short-term price fluctuations for SCYX.Check DERM's competition here

SCYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SCYX stands at 36M. In comparison, THTX has a market cap of 155.9M. Regarding current trading prices, SCYX is priced at $0.89, while THTX trades at $3.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SCYX currently has a P/E ratio of -1.68, whereas THTX's P/E ratio is -17.84. In terms of profitability, SCYX's ROE is -0.19%, compared to THTX's ROE of +0.47%. Regarding short-term risk, SCYX is more volatile compared to THTX. This indicates potentially higher risk in terms of short-term price fluctuations for SCYX.Check THTX's competition here

SCYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SCYX stands at 36M. In comparison, TKNO has a market cap of 149.5M. Regarding current trading prices, SCYX is priced at $0.89, while TKNO trades at $2.93.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SCYX currently has a P/E ratio of -1.68, whereas TKNO's P/E ratio is -8.72. In terms of profitability, SCYX's ROE is -0.19%, compared to TKNO's ROE of -0.23%. Regarding short-term risk, SCYX is more volatile compared to TKNO. This indicates potentially higher risk in terms of short-term price fluctuations for SCYX.Check TKNO's competition here

SCYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SCYX stands at 36M. In comparison, SCTL has a market cap of 116.1M. Regarding current trading prices, SCYX is priced at $0.89, while SCTL trades at $1.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SCYX currently has a P/E ratio of -1.68, whereas SCTL's P/E ratio is -7.86. In terms of profitability, SCYX's ROE is -0.19%, compared to SCTL's ROE of -0.22%. Regarding short-term risk, SCYX is more volatile compared to SCTL. This indicates potentially higher risk in terms of short-term price fluctuations for SCYX.Check SCTL's competition here

SCYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SCYX stands at 36M. In comparison, CRDL has a market cap of 113.9M. Regarding current trading prices, SCYX is priced at $0.89, while CRDL trades at $1.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SCYX currently has a P/E ratio of -1.68, whereas CRDL's P/E ratio is -3.40. In terms of profitability, SCYX's ROE is -0.19%, compared to CRDL's ROE of -2.03%. Regarding short-term risk, SCYX is more volatile compared to CRDL. This indicates potentially higher risk in terms of short-term price fluctuations for SCYX.Check CRDL's competition here

SCYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SCYX stands at 36M. In comparison, PROC has a market cap of 102.1M. Regarding current trading prices, SCYX is priced at $0.89, while PROC trades at $1.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SCYX currently has a P/E ratio of -1.68, whereas PROC's P/E ratio is 1.53. In terms of profitability, SCYX's ROE is -0.19%, compared to PROC's ROE of -2.22%. Regarding short-term risk, SCYX is more volatile compared to PROC. This indicates potentially higher risk in terms of short-term price fluctuations for SCYX.Check PROC's competition here

SCYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SCYX stands at 36M. In comparison, OPTN has a market cap of 97.2M. Regarding current trading prices, SCYX is priced at $0.89, while OPTN trades at $9.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SCYX currently has a P/E ratio of -1.68, whereas OPTN's P/E ratio is -4.42. In terms of profitability, SCYX's ROE is -0.19%, compared to OPTN's ROE of +0.47%. Regarding short-term risk, SCYX is more volatile compared to OPTN. This indicates potentially higher risk in terms of short-term price fluctuations for SCYX.Check OPTN's competition here

SCYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SCYX stands at 36M. In comparison, ALVOW has a market cap of 95.9M. Regarding current trading prices, SCYX is priced at $0.89, while ALVOW trades at $0.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SCYX currently has a P/E ratio of -1.68, whereas ALVOW's P/E ratio is N/A. In terms of profitability, SCYX's ROE is -0.19%, compared to ALVOW's ROE of -0.26%. Regarding short-term risk, SCYX is less volatile compared to ALVOW. This indicates potentially lower risk in terms of short-term price fluctuations for SCYX.Check ALVOW's competition here

SCYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SCYX stands at 36M. In comparison, ZOM has a market cap of 95.3M. Regarding current trading prices, SCYX is priced at $0.89, while ZOM trades at $0.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SCYX currently has a P/E ratio of -1.68, whereas ZOM's P/E ratio is -1.62. In terms of profitability, SCYX's ROE is -0.19%, compared to ZOM's ROE of -0.59%. Regarding short-term risk, SCYX is more volatile compared to ZOM. This indicates potentially higher risk in terms of short-term price fluctuations for SCYX.Check ZOM's competition here

SCYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SCYX stands at 36M. In comparison, GRVI has a market cap of 88.9M. Regarding current trading prices, SCYX is priced at $0.89, while GRVI trades at $4.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SCYX currently has a P/E ratio of -1.68, whereas GRVI's P/E ratio is 26.05. In terms of profitability, SCYX's ROE is -0.19%, compared to GRVI's ROE of -1.20%. Regarding short-term risk, SCYX is more volatile compared to GRVI. This indicates potentially higher risk in terms of short-term price fluctuations for SCYX.Check GRVI's competition here

SCYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SCYX stands at 36M. In comparison, ASRT has a market cap of 74M. Regarding current trading prices, SCYX is priced at $0.89, while ASRT trades at $11.81.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SCYX currently has a P/E ratio of -1.68, whereas ASRT's P/E ratio is -2.56. In terms of profitability, SCYX's ROE is -0.19%, compared to ASRT's ROE of -0.27%. Regarding short-term risk, SCYX is more volatile compared to ASRT. This indicates potentially higher risk in terms of short-term price fluctuations for SCYX.Check ASRT's competition here

SCYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SCYX stands at 36M. In comparison, ZYNE has a market cap of 70.1M. Regarding current trading prices, SCYX is priced at $0.89, while ZYNE trades at $1.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SCYX currently has a P/E ratio of -1.68, whereas ZYNE's P/E ratio is -1.65. In terms of profitability, SCYX's ROE is -0.19%, compared to ZYNE's ROE of -0.59%. Regarding short-term risk, SCYX is more volatile compared to ZYNE. This indicates potentially higher risk in terms of short-term price fluctuations for SCYX.Check ZYNE's competition here

SCYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SCYX stands at 36M. In comparison, SSIC has a market cap of 66.7M. Regarding current trading prices, SCYX is priced at $0.89, while SSIC trades at $10.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SCYX currently has a P/E ratio of -1.68, whereas SSIC's P/E ratio is 11.93. In terms of profitability, SCYX's ROE is -0.19%, compared to SSIC's ROE of -0.00%. Regarding short-term risk, SCYX is more volatile compared to SSIC. This indicates potentially higher risk in terms of short-term price fluctuations for SCYX.Check SSIC's competition here

SCYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SCYX stands at 36M. In comparison, VLNS has a market cap of 61.5M. Regarding current trading prices, SCYX is priced at $0.89, while VLNS trades at $0.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SCYX currently has a P/E ratio of -1.68, whereas VLNS's P/E ratio is -1.03. In terms of profitability, SCYX's ROE is -0.19%, compared to VLNS's ROE of N/A. Regarding short-term risk, SCYX is more volatile compared to VLNS. This indicates potentially higher risk in terms of short-term price fluctuations for SCYX.Check VLNS's competition here

SCYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SCYX stands at 36M. In comparison, DRRX has a market cap of 59.3M. Regarding current trading prices, SCYX is priced at $0.89, while DRRX trades at $1.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SCYX currently has a P/E ratio of -1.68, whereas DRRX's P/E ratio is -4.44. In terms of profitability, SCYX's ROE is -0.19%, compared to DRRX's ROE of -0.71%. Regarding short-term risk, SCYX is more volatile compared to DRRX. This indicates potentially higher risk in terms of short-term price fluctuations for SCYX.Check DRRX's competition here

SCYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SCYX stands at 36M. In comparison, JUPW has a market cap of 49.3M. Regarding current trading prices, SCYX is priced at $0.89, while JUPW trades at $1.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SCYX currently has a P/E ratio of -1.68, whereas JUPW's P/E ratio is -2.41. In terms of profitability, SCYX's ROE is -0.19%, compared to JUPW's ROE of -0.99%. Regarding short-term risk, SCYX is less volatile compared to JUPW. This indicates potentially lower risk in terms of short-term price fluctuations for SCYX.Check JUPW's competition here

SCYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SCYX stands at 36M. In comparison, CPIX has a market cap of 45.5M. Regarding current trading prices, SCYX is priced at $0.89, while CPIX trades at $3.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SCYX currently has a P/E ratio of -1.68, whereas CPIX's P/E ratio is -16.00. In terms of profitability, SCYX's ROE is -0.19%, compared to CPIX's ROE of -0.11%. Regarding short-term risk, SCYX is more volatile compared to CPIX. This indicates potentially higher risk in terms of short-term price fluctuations for SCYX.Check CPIX's competition here

SCYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SCYX stands at 36M. In comparison, INCR has a market cap of 43.7M. Regarding current trading prices, SCYX is priced at $0.89, while INCR trades at $0.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SCYX currently has a P/E ratio of -1.68, whereas INCR's P/E ratio is -1.60. In terms of profitability, SCYX's ROE is -0.19%, compared to INCR's ROE of -0.17%. Regarding short-term risk, SCYX is more volatile compared to INCR. This indicates potentially higher risk in terms of short-term price fluctuations for SCYX.Check INCR's competition here

SCYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SCYX stands at 36M. In comparison, QLI has a market cap of 38.7M. Regarding current trading prices, SCYX is priced at $0.89, while QLI trades at $5.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SCYX currently has a P/E ratio of -1.68, whereas QLI's P/E ratio is -4.92. In terms of profitability, SCYX's ROE is -0.19%, compared to QLI's ROE of -0.16%. Regarding short-term risk, SCYX is more volatile compared to QLI. This indicates potentially higher risk in terms of short-term price fluctuations for SCYX.Check QLI's competition here

SCYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SCYX stands at 36M. In comparison, IXHL has a market cap of 37.3M. Regarding current trading prices, SCYX is priced at $0.89, while IXHL trades at $3.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SCYX currently has a P/E ratio of -1.68, whereas IXHL's P/E ratio is -0.15. In terms of profitability, SCYX's ROE is -0.19%, compared to IXHL's ROE of -1.99%. Regarding short-term risk, SCYX is less volatile compared to IXHL. This indicates potentially lower risk in terms of short-term price fluctuations for SCYX.Check IXHL's competition here

SCYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SCYX stands at 36M. In comparison, ZYBT has a market cap of 37.2M. Regarding current trading prices, SCYX is priced at $0.89, while ZYBT trades at $0.73.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SCYX currently has a P/E ratio of -1.68, whereas ZYBT's P/E ratio is -13.07. In terms of profitability, SCYX's ROE is -0.19%, compared to ZYBT's ROE of +0.04%. Regarding short-term risk, SCYX is less volatile compared to ZYBT. This indicates potentially lower risk in terms of short-term price fluctuations for SCYX.Check ZYBT's competition here

SCYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SCYX stands at 36M. In comparison, RMTI has a market cap of 35.3M. Regarding current trading prices, SCYX is priced at $0.89, while RMTI trades at $0.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SCYX currently has a P/E ratio of -1.68, whereas RMTI's P/E ratio is -4.98. In terms of profitability, SCYX's ROE is -0.19%, compared to RMTI's ROE of -0.17%. Regarding short-term risk, SCYX is more volatile compared to RMTI. This indicates potentially higher risk in terms of short-term price fluctuations for SCYX.Check RMTI's competition here

SCYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SCYX stands at 36M. In comparison, HEXO has a market cap of 31.2M. Regarding current trading prices, SCYX is priced at $0.89, while HEXO trades at $0.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SCYX currently has a P/E ratio of -1.68, whereas HEXO's P/E ratio is -0.26. In terms of profitability, SCYX's ROE is -0.19%, compared to HEXO's ROE of -2.06%. Regarding short-term risk, SCYX is more volatile compared to HEXO. This indicates potentially higher risk in terms of short-term price fluctuations for SCYX.Check HEXO's competition here

SCYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SCYX stands at 36M. In comparison, TXMD has a market cap of 25.1M. Regarding current trading prices, SCYX is priced at $0.89, while TXMD trades at $2.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SCYX currently has a P/E ratio of -1.68, whereas TXMD's P/E ratio is 217.00. In terms of profitability, SCYX's ROE is -0.19%, compared to TXMD's ROE of +0.01%. Regarding short-term risk, SCYX is more volatile compared to TXMD. This indicates potentially higher risk in terms of short-term price fluctuations for SCYX.Check TXMD's competition here

SCYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SCYX stands at 36M. In comparison, CYTH has a market cap of 23.6M. Regarding current trading prices, SCYX is priced at $0.89, while CYTH trades at $0.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SCYX currently has a P/E ratio of -1.68, whereas CYTH's P/E ratio is -0.80. In terms of profitability, SCYX's ROE is -0.19%, compared to CYTH's ROE of -7.30%. Regarding short-term risk, SCYX is more volatile compared to CYTH. This indicates potentially higher risk in terms of short-term price fluctuations for SCYX.Check CYTH's competition here

SCYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SCYX stands at 36M. In comparison, AYTU has a market cap of 20.6M. Regarding current trading prices, SCYX is priced at $0.89, while AYTU trades at $2.62.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SCYX currently has a P/E ratio of -1.68, whereas AYTU's P/E ratio is -0.74. In terms of profitability, SCYX's ROE is -0.19%, compared to AYTU's ROE of -1.07%. Regarding short-term risk, SCYX is more volatile compared to AYTU. This indicates potentially higher risk in terms of short-term price fluctuations for SCYX.Check AYTU's competition here

SCYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SCYX stands at 36M. In comparison, APUS has a market cap of 20.5M. Regarding current trading prices, SCYX is priced at $0.89, while APUS trades at $1.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SCYX currently has a P/E ratio of -1.68, whereas APUS's P/E ratio is -3.98. In terms of profitability, SCYX's ROE is -0.19%, compared to APUS's ROE of -1.40%. Regarding short-term risk, SCYX is less volatile compared to APUS. This indicates potentially lower risk in terms of short-term price fluctuations for SCYX.Check APUS's competition here

SCYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SCYX stands at 36M. In comparison, EVOK has a market cap of 18.9M. Regarding current trading prices, SCYX is priced at $0.89, while EVOK trades at $11.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SCYX currently has a P/E ratio of -1.68, whereas EVOK's P/E ratio is -7.97. In terms of profitability, SCYX's ROE is -0.19%, compared to EVOK's ROE of -1.01%. Regarding short-term risk, SCYX is more volatile compared to EVOK. This indicates potentially higher risk in terms of short-term price fluctuations for SCYX.Check EVOK's competition here

SCYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SCYX stands at 36M. In comparison, TLPH has a market cap of 16.3M. Regarding current trading prices, SCYX is priced at $0.89, while TLPH trades at $0.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SCYX currently has a P/E ratio of -1.68, whereas TLPH's P/E ratio is -2.10. In terms of profitability, SCYX's ROE is -0.19%, compared to TLPH's ROE of -1.26%. Regarding short-term risk, SCYX is more volatile compared to TLPH. This indicates potentially higher risk in terms of short-term price fluctuations for SCYX.Check TLPH's competition here

SCYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SCYX stands at 36M. In comparison, ACRX has a market cap of 14.6M. Regarding current trading prices, SCYX is priced at $0.89, while ACRX trades at $0.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SCYX currently has a P/E ratio of -1.68, whereas ACRX's P/E ratio is -0.31. In terms of profitability, SCYX's ROE is -0.19%, compared to ACRX's ROE of -1.26%. Regarding short-term risk, SCYX is less volatile compared to ACRX. This indicates potentially lower risk in terms of short-term price fluctuations for SCYX.Check ACRX's competition here

SCYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SCYX stands at 36M. In comparison, AGRX has a market cap of 10.4M. Regarding current trading prices, SCYX is priced at $0.89, while AGRX trades at $1.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SCYX currently has a P/E ratio of -1.68, whereas AGRX's P/E ratio is -0.89. In terms of profitability, SCYX's ROE is -0.19%, compared to AGRX's ROE of +1.32%. Regarding short-term risk, SCYX is more volatile compared to AGRX. This indicates potentially higher risk in terms of short-term price fluctuations for SCYX.Check AGRX's competition here

SCYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SCYX stands at 36M. In comparison, BFRI has a market cap of 10.1M. Regarding current trading prices, SCYX is priced at $0.89, while BFRI trades at $0.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SCYX currently has a P/E ratio of -1.68, whereas BFRI's P/E ratio is -0.56. In terms of profitability, SCYX's ROE is -0.19%, compared to BFRI's ROE of +29.95%. Regarding short-term risk, SCYX is more volatile compared to BFRI. This indicates potentially higher risk in terms of short-term price fluctuations for SCYX.Check BFRI's competition here

SCYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SCYX stands at 36M. In comparison, COSM has a market cap of 9.7M. Regarding current trading prices, SCYX is priced at $0.89, while COSM trades at $0.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SCYX currently has a P/E ratio of -1.68, whereas COSM's P/E ratio is -0.46. In terms of profitability, SCYX's ROE is -0.19%, compared to COSM's ROE of -0.74%. Regarding short-term risk, SCYX is more volatile compared to COSM. This indicates potentially higher risk in terms of short-term price fluctuations for SCYX.Check COSM's competition here

SCYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SCYX stands at 36M. In comparison, QNTM has a market cap of 9.5M. Regarding current trading prices, SCYX is priced at $0.89, while QNTM trades at $2.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SCYX currently has a P/E ratio of -1.68, whereas QNTM's P/E ratio is -0.26. In terms of profitability, SCYX's ROE is -0.19%, compared to QNTM's ROE of -3.85%. Regarding short-term risk, SCYX is more volatile compared to QNTM. This indicates potentially higher risk in terms of short-term price fluctuations for SCYX.Check QNTM's competition here

SCYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SCYX stands at 36M. In comparison, NLTX has a market cap of 8.2M. Regarding current trading prices, SCYX is priced at $0.89, while NLTX trades at $3.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SCYX currently has a P/E ratio of -1.68, whereas NLTX's P/E ratio is -0.28. In terms of profitability, SCYX's ROE is -0.19%, compared to NLTX's ROE of -0.40%. Regarding short-term risk, SCYX is more volatile compared to NLTX. This indicates potentially higher risk in terms of short-term price fluctuations for SCYX.Check NLTX's competition here

SCYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SCYX stands at 36M. In comparison, YCBD has a market cap of 7.4M. Regarding current trading prices, SCYX is priced at $0.89, while YCBD trades at $0.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SCYX currently has a P/E ratio of -1.68, whereas YCBD's P/E ratio is 1.18. In terms of profitability, SCYX's ROE is -0.19%, compared to YCBD's ROE of -0.41%. Regarding short-term risk, SCYX is more volatile compared to YCBD. This indicates potentially higher risk in terms of short-term price fluctuations for SCYX.Check YCBD's competition here

SCYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SCYX stands at 36M. In comparison, LCI has a market cap of 7.4M. Regarding current trading prices, SCYX is priced at $0.89, while LCI trades at $0.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SCYX currently has a P/E ratio of -1.68, whereas LCI's P/E ratio is -0.04. In terms of profitability, SCYX's ROE is -0.19%, compared to LCI's ROE of +1.66%. Regarding short-term risk, SCYX is less volatile compared to LCI. This indicates potentially lower risk in terms of short-term price fluctuations for SCYX.Check LCI's competition here

SCYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SCYX stands at 36M. In comparison, BGXX has a market cap of 7.3M. Regarding current trading prices, SCYX is priced at $0.89, while BGXX trades at $0.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SCYX currently has a P/E ratio of -1.68, whereas BGXX's P/E ratio is -0.76. In terms of profitability, SCYX's ROE is -0.19%, compared to BGXX's ROE of -1.16%. Regarding short-term risk, SCYX is more volatile compared to BGXX. This indicates potentially higher risk in terms of short-term price fluctuations for SCYX.Check BGXX's competition here

SCYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SCYX stands at 36M. In comparison, ADMP has a market cap of 7.3M. Regarding current trading prices, SCYX is priced at $0.89, while ADMP trades at $0.78.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SCYX currently has a P/E ratio of -1.68, whereas ADMP's P/E ratio is -0.08. In terms of profitability, SCYX's ROE is -0.19%, compared to ADMP's ROE of -2.09%. Regarding short-term risk, SCYX is more volatile compared to ADMP. This indicates potentially higher risk in terms of short-term price fluctuations for SCYX.Check ADMP's competition here

SCYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SCYX stands at 36M. In comparison, GELS has a market cap of 7.2M. Regarding current trading prices, SCYX is priced at $0.89, while GELS trades at $0.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SCYX currently has a P/E ratio of -1.68, whereas GELS's P/E ratio is -1.56. In terms of profitability, SCYX's ROE is -0.19%, compared to GELS's ROE of -0.43%. Regarding short-term risk, SCYX is more volatile compared to GELS. This indicates potentially higher risk in terms of short-term price fluctuations for SCYX.Check GELS's competition here

SCYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SCYX stands at 36M. In comparison, SBFM has a market cap of 5.4M. Regarding current trading prices, SCYX is priced at $0.89, while SBFM trades at $1.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SCYX currently has a P/E ratio of -1.68, whereas SBFM's P/E ratio is 0.21. In terms of profitability, SCYX's ROE is -0.19%, compared to SBFM's ROE of -0.25%. Regarding short-term risk, SCYX is more volatile compared to SBFM. This indicates potentially higher risk in terms of short-term price fluctuations for SCYX.Check SBFM's competition here

SCYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SCYX stands at 36M. In comparison, MNK has a market cap of 4.5M. Regarding current trading prices, SCYX is priced at $0.89, while MNK trades at $0.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SCYX currently has a P/E ratio of -1.68, whereas MNK's P/E ratio is -0.44. In terms of profitability, SCYX's ROE is -0.19%, compared to MNK's ROE of +0.11%. Regarding short-term risk, SCYX is less volatile compared to MNK. This indicates potentially lower risk in terms of short-term price fluctuations for SCYX.Check MNK's competition here

SCYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SCYX stands at 36M. In comparison, EGRX has a market cap of 4.4M. Regarding current trading prices, SCYX is priced at $0.89, while EGRX trades at $0.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SCYX currently has a P/E ratio of -1.68, whereas EGRX's P/E ratio is 4.87. In terms of profitability, SCYX's ROE is -0.19%, compared to EGRX's ROE of +0.17%. Regarding short-term risk, SCYX is more volatile compared to EGRX. This indicates potentially higher risk in terms of short-term price fluctuations for SCYX.Check EGRX's competition here

SCYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SCYX stands at 36M. In comparison, SNOA has a market cap of 4.2M. Regarding current trading prices, SCYX is priced at $0.89, while SNOA trades at $2.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SCYX currently has a P/E ratio of -1.68, whereas SNOA's P/E ratio is -1.26. In terms of profitability, SCYX's ROE is -0.19%, compared to SNOA's ROE of -0.86%. Regarding short-term risk, SCYX is more volatile compared to SNOA. This indicates potentially higher risk in terms of short-term price fluctuations for SCYX.Check SNOA's competition here

SCYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SCYX stands at 36M. In comparison, FLGC has a market cap of 4.2M. Regarding current trading prices, SCYX is priced at $0.89, while FLGC trades at $7.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SCYX currently has a P/E ratio of -1.68, whereas FLGC's P/E ratio is -0.19. In terms of profitability, SCYX's ROE is -0.19%, compared to FLGC's ROE of -0.22%. Regarding short-term risk, SCYX is less volatile compared to FLGC. This indicates potentially lower risk in terms of short-term price fluctuations for SCYX.Check FLGC's competition here